Guidelines on the benefit-risk assessment of the presence of phthalates in certain medical devices covering phthalates which are carcinogenic, mutagenic, toxic to reproduction (CMR) or have endocrine-disrupting (ED) properties Comment uri icon

authors

  • De Jong, WH
  • De Jong, WH
  • Borges, T
  • Ion, RM
  • Panagiotakos, D
  • Testai, E
  • Vermeire, T
  • Bernauer, U
  • Rousselle, C
  • Bégué, Sté
  • Kopperud, HM
  • Milana, MR
  • Schmidt, T
  • Pignatti, F
  • Stoyanova, E
  • Volk, K
  • Bertollini, R
  • De Voogt, P
  • Duarte-Davidson, R
  • Hoet, P
  • Kraetke, R
  • Proykova, A
  • Samaras, T
  • Scott, M
  • Slama, R
  • Vighi, M
  • Zacharo, S

publication date

  • March 2020